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Poorly water soluble active pharmaceutical
ingredients (APIs) may undergo incomplete dissolu-
tion in gastrointestinal fluids and thus be only par-
tially absorbed into systemic circulation. As it is
reported, ca. 40% of commercialized APIs and
almost 70% of potential new drugs are poorly water
soluble (1). Formation of solid dispersions that leads
to dispersion of insoluble APIs among well soluble
polymeric matrix is potential approach to enhance
their bioavailability. The processing methods like
fast cooling from melting, spray drying or
micronization, may result in crystalline drugs amor-
phization. However, solids are often characterized
by combined properties, i.e. partially crystalline,
containing stable and metastable forms and partially
amorphous. The result of applied process can be
very complexed and tough to control (2).
Bicalutamide (BCL) is a non-steroidal antian-
drogen used in treatment of prostate cancer (3). It is
administered orally as 50 mg tablets. Since the drug
is practically insoluble in water (4 µg/mL at 37OC)
(4) and has high membrane permeability (LogP
2.92) (5), it is assigned to class II according to
Biopharmaceutical Classification System (6). Its
pKa = 12 is higher than the upper limit of intestinal
fluids pH, therefore BCL solubility does not seem to
be facilitated in any region of gastrointestinal tract
(5). The BCL crystals exhibit polymorphism - forms
I and II have already been identified (7-9). While
form I referred as monoclinic is more stable than tri-
clinic form II, the form II is 2.4-times more soluble
than form I. Nevertheless, both polymorphs are very
poorly soluble in aqueous media (10). 
BCL dissolution rate can be improved by
development of API-cyclodextrins complexes or
formulation of solid dispersions. Complexation of
BCL with fl-cyclodextrin in 1 : 1, 1 : 2 and 1 : 5 w/w
ratios was carried out by three techniques, i.e., sol-
vent evaporation, spray-drying and kneading. The
most significant improvement of drug dissolution
rate was observed for 1 : 5 inclusion complex pre-
pared by kneading (11).
BCL solid dispersions were formulated by hot
melt extrusion, solvent evaporation or melting meth-
ods. Gavin et al. described the manufacture of BCL
and polyvinylpyrrolidone K25 (PVP) systems in 1 :
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10, 2 : 10 and 3 : 10 w/w ratios prepared by hot melt
extrusion. The drug dissolution enhancement was
attributed to BCL amorphization and the extrudatesí
wettability improvement caused by PVP hydrophilic
matrix (12). 
The solvent evaporation method was applied
for solid dispersions preparation containing BCL and
PVP or PoloxamerÆ 407 and F68 (PLX) (13-15).
The drug-carrier ratio was the most important factor
affecting the drug dissolution rate. In particular, the
highest dissolution rate was observed for solid dis-
persion prepared in 1 : 5 w/w ratio, for both carriers
i.e., PVP K30 and PLX 407. This phenomenon may
be caused by transformation of crystalline BCL into
amorphous form. The other study demonstrated that
improvement of BCL dissolution rate was the most
effective for the 1 : 1 BCLñPoloxamerÆ F68 solid
dispersion prepared by melting method (15). The
effect was attributed to partial amorphization of the
API. Surprisingly, increase in PoloxamerÆ F68
quantity resulted in prolongation of BCL dissolution
that was caused by the gelling of PLX. 
Improvement in BCL dissolution rate was also
achieved by solid dispersion prepared with
AeroperlÆ 300, a highly porous grade of spherical-
ly shaped fumed silica and hydrophilic Macrogol
Figure 1. SEM micrographs of: a) Bicalutamide (BCL), b) PoloxamerÆ 407 (PLX), c) solid dispersion made by melting method (BCL/PLX
Melt), d) solid dispersion made with supercritical CO2 (BCL/PLX SCF)
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400. The API and Macrogol 400 were dissolved in
an organic solvent - acetone, and then mixed with
silica. After the solvent was evaporated, particles of
amorphous BCL surrounded by Macrogol 400 were
uniformly adsorbed within the silica pores. As a
result, the dissolution rate of BCL was improved 15-
fold in comparison to unprocessed active substance.
The effect was attributed to amorphization of the
API and the phase stabilization by the drug incorpo-
rated into AeroperlÆ 300 pores, as well as by
improvement of the particles wetting by the pres-
ence of Macrogol 400 (16).
In recent years, the supercritical fluid (SCF)
technique was applied to solid dispersion formation.
This method has become popular in the pharmaceu-
tical sciences and recognizable by industry.
Numerous applications, e.g., extraction of thermally
sensitive substances, drug particlesí size reduction,
mixing and complexation (17-19) may be much eas-
ier with SCF technology. Carbon dioxide (CO2), is
the most popular medium, since it is non-toxic, non-
flammable, inexpensive, easy to remove and pos-
sesses low critical temperature and pressure (31.1OC
and 73.8 bar). The molecule has linear shape (O-C-
O), so its dipolar momentum is zero and the
quadrupolar momentum is very small. Hence, the
nonpolar (lipophilic) substances can be easily
extracted from polar (hydrophilic) matrices simply
by dissolution in supercritical CO2 at relatively low
temperature. Such properties enable supercritical
carbon dioxide (scCO2) to replace organic solvents
as well as prevent drug degradation (20, 21). Up to
now the supercritical fluid technique was success-
fully applied for dissolution enhancement of carba-
mazepine (22), nifedipine (23) and furosemide (24). 
The present study was aimed to improve solu-
bility and dissolution rate of bicalutamide by prepa-
ration of solid dispersion using SCF and melting
method. PoloxamerÆ 407, a low-meltable polymer-
ic surfactant was chosen as a carrier. The effect of
preparation method on drug dissolution was investi-
gated. The solid dispersions and physical mixture
containing BCL and PLX in 1 : 1 w/w ratio were
characterized by scanning electron microscopy
Table 1. Properties of pure bicalutamide and the binary systems. Abbreviations: BCL - bicalutamide, PLX -
Poloxamer, PhM - physical mixture, Melt - melting method, SCF - supercritical carbon dioxide method. 
Sample Appearance
BCL white, crystalline powder
BCL/PLX PhM white powder, crystals of BCL are visible
BCL/PLX Melt white, waxy, easily pulverized
BCL/PLX SCF white, free flowing powder
Table 2. The enthalpies ∆H and temperatures Tonset (in parentheses) of tested samples. With the exception of
PLX407 all of the determined values were normalized to the weight of bicalutamide.
Sample ∆H [mJ/mg] (Tonset [OC])
BCL - 113.0 (194.20)
PLX 129.0 (51.93) -
BCL/PLX SCF 139.0 (50.34) 61.0 (159.90)
BCL/PLX PhM 92.3 (52.22) 150.0 (181.90)
Table 3. Kinetics data. 
Sample Equation constant DE
BCL 0.39 8.13
BCL/PLX PhM 1.04 24.38
BCL/PLX Melt 2.26 39.79
BCL/PLX SCF 3.33 65.18
DE - dissolution efficiency
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(SEM), X-ray powder diffraction (XRPD) and dif-
ferential scanning calorimetry (DSC). 
EXPERIMENTAL
Materials
Bicalutamide (BCL, Pharmaceutical Research
Institute, Poland), PoloxamerÆ 407 (PLX, BASF,
Germany), carbon dioxide in form of dry ice (Linde,
Poland). All materials were of analytical grade.
Procedures
Two methods, i.e., supercritical carbon dioxide
method or melting method were used for preparation
of bicalutamide and PoloxamerÆ 407 solid disper-
sions while the physical mixture was prepared by
mixing with carrier in a mortar. Samples were pre-
pared in 1 : 1 (w/w) drug to carrier ratio.
Supercritical carbon dioxide method
The materials, BCL and PLX were loaded into
high pressure reactor BR-300 (Berghof Products +
Instruments GmbH, Germany) equipped with mag-
netic stirrer MR Hei-Standard (Heidolph Instru-
ments, Germany) and thermometer CHY 700T
(CHY Firemate Co., Taiwan). The calculated quan-
tity of CO2 in form of dry ice was placed in the reac-
tor to achieve supercritical pressure of 130 bar at
60OC. Temperature, pressure, and mixing speed
were monitored during the process. 
Melting method
Polymer was melted in a water bath and BCL
was poured while stirring. Dispersion of BCL in
melted polymer was cooled down to the ambient
temperature. After 24 h of storage in desiccator the
solidified mass was crushed, pulverized and sieved
trough the 500 µm sieve.
Characterization of solid dispersion
Morphological analysis by scanning electron
microscopy 
Particles were examined using scanning elec-
tron microscope S-4700 (Hitachi Inc., Japan). The
powder was adhered to a sample holder by a double-
sided carbon tape and coated with gold using the
208 HR sputter coater (Cressington Scientific,
USA). The images were taken at the magnification
of 50× and 400×.
X-ray powder diffraction analysis
The diffraction pattern was recorded in terms of
2θ at a range of 2O - 60O using PW 1830 diffractome-
ter (Philips, The Netherlands) equipped with nickel
filtered Cu-Kα radiation (λ = 1.5406 Å). Diffraction
patterns used later for Rietveld analysis were record-
ed with the rate of 0.02O/10 s. Analyses were per-
formed in MAUD (25) environment, FITYK (26) was
used as auxiliary software for data preparation.
Differential scanning calorimetry analysis
The measurements were performed using
DSC7020 calorimeter (Hitachi Inc., Japan)
equipped with dedicated electric cooling unit. The
apparatus was calibrated using indium and tin stan-
dards. The analyses were performed in nitrogen
atmosphere with a flow rate of 50 mL/min. The 6.8
- 8.1 mg of samples were placed in aluminum pans
Figure 2. Experimental XRPD pattern of bicalutamide sample, simulated patterns of polymorph I and polymorph II. Structural data for
polymorphs I and II were taken from 2014 CCDC database
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and sealed. The following thermal protocol was
used: equilibrating at 25OC for 15 min, then heating
to 220OC, except PLX, which was heated to 200OC,
at heating rate of 10OC/min. With the exception of
PLX all determined ∆H values of samples within the
study were normalized to the weight of BCL.
Solubility studies
An excess of drug or binary system was dis-
persed in 25 mL of distilled water in a conical flask.
The suspension was shaken at room temperature
using the KS 130 Basic shaker (IKA, Germany) for
at least 24 h to achieve the equilibrium solubility.
Samples were centrifuged at 3600 rpm for 30 min in
the MPW 221 apparatus (MPW, Poland) and filtered
through a 0.2 µm membrane filter. The diluted sam-
ples were assayed at 270 nm with UV-VIS spec-
trophotometer V-500 (Jasco Analytical Instruments,
USA). The reported data represents the averages
from three series of measurements.
Dissolution rate studies
Dissolution studies were carried out using the
method recommended by the FDA for BCL tablets,
i.e. USP type II apparatus (paddle) at 50 rpm, 1000
mL of water containing 1% SLS at 37 ± 0.5OC. The
analysis was performed in the SR8 Plus type II
Dissolution Test Station (Hanson Research, USA).
A certain amount of powder samples, i.e., solid dis-
persions, physical mixtures or pure drug, equivalent
to 50 mg of active substance, were poured into the
beakers. 5 mL of solution were withdrawn from
each dissolution vessel at predefined intervals, fil-
tered, diluted and assayed spectrophotometrically at
λ = 272 nm. After collection of the each sample the
dissolution medium was replaced with the same vol-
ume of dissolution medium. The tests were carried
out in triplicate. The dissolution data were analyzed
by Open Source software KinetDS 3.0 with standard
settings including non-linear regression methods.
Different models i.e., zero order, first order, second
Figure 3. Diffractograms of: crystalline bicalutamide (BCL), PoloxamerÆ 407 (PLX), solid dispersions BCL/PLX SCF and BCL/PLX
Melt, physical mixture of bicalutamide and PLX (BCL/PLX PhM), Presented intensities are not to scale
Figure 4. DSC endothermic curves of studied samples: crystalline BCL (green line), PLX (solid gray line), physical mixture (blue dotted
line), BCL/PLX melting method (purple dotted line) and scCO2 treated product (red line)
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order, third order, Korsmeyer-Peppas model, y =
a∑ln(x) + b model, Weibull models, Hixson-
Crowell, Higuchi, Baker-Lonsdale, Michaelis-
Menten, Hill, were evaluated to found the best fit
to obtained data (27).
RESULTS AND DISCCUSSION
Effects of preparation methods on samples physi-
cal state
The both methods i.e., supercritical carbon
dioxide (SCF) and melting (Melt) were suitable for
preparation of BCL solid dispersions, however they
impacted the samples properties. Referring to table
1, solid dispersion prepared by SCF was in form of
freely flowing powder, while prepared by melting
method was a little waxy but easy to pulverize.
The SEM micrographs of raw materials and
solid dispersions are compared in Figure 1.
Bicalutamide (Fig. 1a) appears as aggregates com-
posed of plate-like crystallites of different size, from
15 µm up to 200 µm in length. The individual plates
exhibit shape of elongated hexagons. PoloxamerÆ
407 (Fig. 1b) is in form of smooth particles of
droplet-like elliptical shape. The solid dispersion
obtained by melting (Fig. 1c) demonstrates aggre-
gates with sharp edges covered by carrier, however
a fraction of uncovered crystals is also noticeable.
Reduction of particle size was observed. The solid
dispersion prepared by SCF method (Fig. 1d) shows
random aggregates of small block-like objects with
edges rounded as if they were covered with polymer
layer. It is worth to emphasize that significant frac-
tion of the grains has smaller size than the drug sub-
stance presented in Figure 1a. In our opinion during
SCF process PLX covered the drug crystals entirely
and after cooling and depressurization a partial
recrystallization of BCL occured.
In the crystallographic databases two poly-
morphs of BCL are listed. The first reference struc-
ture corresponds to plate-like crystals (7) while the
second to the prism-like ones (3). The micrograph in
Figure 1a presents plate-like crystals of the non-treat-
ed BCL, which suggests that structure of polymorph
I is dominant. The finding is fully consistent with the
set of diffraction patterns presented in Figure 2.
The XRPD patterns of pure BCL, PLX, solid
dispersions prepared by the both methods and corre-
sponding physical mixture are shown in Figure 3.
Broad peaks in PLX diffractogram are typical for
polymeric substances, in which structural elements
show only short-range ordering. These peaks were
mathematically removed from diffraction patterns of
binary systems with right proportion to their weight
fraction before further interpretation of powder dif-
fractograms. The curve obtained for physical mix-
ture indicate unchanged diffraction pattern of BCL.
This is confirmed by analysis of diffractogram
appearing after removal of PLX results from the
curve of physical mixture. The diffraction pattern of
Figure 5. Dissolution rate profiles tested for non-processed bicalutamide (BCL), solid dispersions (BCL/PLX) prepared by melting (Melt),
the supercritical carbon dioxide method (SCF) or by physical mixing (PhM). Method: Ph. Eur. ap. 2, 50 rpm, 1000 mL of 1% SLS solu-
tion in water
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the SCF treated sample becomes more complex. It
reveals that BCL peaks are broader than observed in
the unprocessed substance. The Scherrer formula
was used to determine mean diameter of monocrys-
tal zones:
0.89 λ
D = ññññññññññññ
B cos θ
where: D stands for the mean diameter of monocrys-
tal, λ for wavelength of X-ray used, B is half-width
of a peak and θ stands for the diffraction angle.
SCF process leads to decrease in monocrys-
talline BCL domains size from 230 ± 7 nm before,
to 170 ± 5 nm after treatment. The comparison of the
XRPD data with SEM micrographs points to the fact
that almost all individual grains of BCL and
BCL/PLX SCF are much larger than monocrystals,
and thus they are considered as polycrystalline
aggregates. At least two mechanisms may be
responsible for lowering of BCL crystal size. The
first is dissolution and subsequent quick recrystal-
lization of the drug during treatment by SCF. It is
supported by Figure 1d which shows the aggregates
composed of tiny crystals, which are all covered
with PLX and stack together. However, the smallest
visible crystals are about 20-times larger than the
mean monocrystallite size. The recrystallization was
so quick that it stopped shortly after nucleation of
BCL crystals. It is worth noting that PLX prevented
formation of larger BCL crystals. Strong interac-
tions between BCL and PLX are also suggested by
the fact that BCL recrystallizes in the shape of
block-like grains (cf. Fig 1d).
The DCS curves of the pure drug, the physical
mixture and the solid dispersions are shown in
Figure 4. The DSC curve of crystalline BCL exhib-
ited a single endothermic response corresponding to
melting of the drug. BCL reveals significant
changes of the melting temperature in the presence
of PLX. Drug and carrier interact strongly even
when physically mixed. In this case (cf. Table 2) the
onset temperature goes down by 12OC (from 194.2
to 181.9OC). Sample treated by SCF is characterized
by onset temperature as low as 159.9OC, which is ca.
34OC lower than the onset temperature of pure bica-
lutamide. The DSC curve of BCL/PLX Melt is sim-
ilar to SCF curve.
The melting energies ∆H recalculated for the
pure drug and obtained for the above mentioned
physical mixture and solid dispersion are 150.0
mJ/mg and 61.0 mJ/mg, respectively. Such a con-
siderable difference (89.0 mJ/mg) and a wide tem-
perature shift indicate destabilization of the crystal
structure of BCL and its partial amorphization. It
means that morphology of both PLX and BCL has
been changed, which has previously been illustrated
in SEM images. The above results indicate that the
treated sample contains BCL as amorphous, small,
recrystallized grains and some unchanged, crys-
talline large grains.
Improvement of bicalutamide dissolution rate
The determined solubility of bicalutamide in
water at 25OC was low, i.e., 3.7 µg/mL. PoloxamerÆ
407 as nonionic surfactant with HLB value 18-23
being usually used as a solubilizer for many active
ingredients should improve the solubility of BCL.
However, in case of physical mixture, solubilizing
effect of PLX on BCL was only slightly pro-
nounced. The solubility of BCL from solid disper-
sion prepared by SCF method was greater than that
of pure drug by a factor of 2.8. 
The results of dissolution studies were in
agreement with solubility data (Fig. 5). Importantly,
in case of solid dispersions the use of PLX led to
improvement of dissolution rate; the highest amount
of BCL was dissolved from solid dispersion pre-
pared by SCF method. After 1 h of testing, the
amount of dissolved BCL was 1.7-times greater than
from samples prepared by melting method and 8-
times greater than from pure drug. At the same time
only 30% of drug dissolved from physical mixture.
The solid dispersion prepared by SCF method
exhibited also higher burst release - 70,9% of drug
after 15 min, twice greater than in the case of solid
dispersion prepared by the melting method. Among
all evaluated kinetic models the best fitting were
found for Korsmeyer-Peppas model. Using it, the
dissolution rate constants were determined. In Table
3 kinetic data obtained for solid dispersions systems,
physical mixture as well as pure drug are presented.
The s data confirm that the SCF method allowed to
enhance the dissolution of BCL in more effective
way that melting method.
The differences among dissolution profiles of
BCL solid dispersion were mostly resulted from
wetting effect of hydrophobic drug crystals sur-
rounded by carrierís hydrophilic particles. The other
reasons of dissolution profiles enhancement was
reduction of particles size by SCF method and par-
tial amorphization of BCL crystals.
CONCLUSIONS
Two methods: supercritical fluid method and
melting method were used for preparation of solid
dispersions containing bicalutamide and Polo-
xamerÆ 407. The formulations were investigated
using scanning electron microscopy, differential
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scanning calorimetry as well as X-ray powder dif-
fraction analyses. The SCF as solvent-free method
proved to remarkable increase in the bicalutamide
solubility and dissolution characteristics. The effects
are attributed to the reduction of the size of drug
crystals and partial amorphization what was con-
firmed by SEM, DSC and X-ray studies.
Application of melting method for preparation
of solid dispersion was not satisfactory for BCL sol-
ubility and dissolution rate enhancement. 
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